CN116390744A - 双功能性超级因子及其用途 - Google Patents

双功能性超级因子及其用途 Download PDF

Info

Publication number
CN116390744A
CN116390744A CN202180050945.2A CN202180050945A CN116390744A CN 116390744 A CN116390744 A CN 116390744A CN 202180050945 A CN202180050945 A CN 202180050945A CN 116390744 A CN116390744 A CN 116390744A
Authority
CN
China
Prior art keywords
seq
bispecific
cancer
cells
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180050945.2A
Other languages
English (en)
Chinese (zh)
Inventor
法赫尔·麦钱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicenna Therapeutics Pte Ltd
Original Assignee
Medicenna Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicenna Therapeutics Pte Ltd filed Critical Medicenna Therapeutics Pte Ltd
Publication of CN116390744A publication Critical patent/CN116390744A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180050945.2A 2020-06-24 2021-06-24 双功能性超级因子及其用途 Pending CN116390744A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063043227P 2020-06-24 2020-06-24
US63/043,227 2020-06-24
US202063093724P 2020-10-19 2020-10-19
US63/093,724 2020-10-19
US202063094322P 2020-10-20 2020-10-20
US63/094,322 2020-10-20
US202163165738P 2021-03-24 2021-03-24
US202163165600P 2021-03-24 2021-03-24
US63/165,600 2021-03-24
US63/165,738 2021-03-24
PCT/CA2021/050872 WO2021258213A1 (en) 2020-06-24 2021-06-24 Bifunctional superkines and uses thereof

Publications (1)

Publication Number Publication Date
CN116390744A true CN116390744A (zh) 2023-07-04

Family

ID=79282489

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180050945.2A Pending CN116390744A (zh) 2020-06-24 2021-06-24 双功能性超级因子及其用途

Country Status (6)

Country Link
US (1) US20230365642A1 (enExample)
EP (1) EP4172216A4 (enExample)
JP (1) JP2023532273A (enExample)
CN (1) CN116390744A (enExample)
CA (1) CA3183825A1 (enExample)
WO (1) WO2021258213A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US20230242607A1 (en) * 2020-07-09 2023-08-03 Eutilex Co., Ltd. Il-2 variants
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250387474A1 (en) * 2022-03-08 2025-12-25 Medicenna Therapeutics Inc. Uses and methods for il-2, il-13, and il-4 cytokine bifunctional molecules
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023248009A1 (en) * 2022-06-21 2023-12-28 Medicenna Therapeutics, Inc. Dosing methods for use with il-2 superagonists, agonists, and fusions thereof
WO2024073435A2 (en) * 2022-09-27 2024-04-04 Anwita Biosciences, Inc. Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2025003770A2 (en) * 2023-06-27 2025-01-02 Medicenna Therapeutics Inc. Il-2 fusion proteins
AU2024330564A1 (en) 2023-08-30 2026-04-02 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850093B1 (en) * 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
US12590133B2 (en) * 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) * 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof

Also Published As

Publication number Publication date
EP4172216A1 (en) 2023-05-03
CA3183825A1 (en) 2021-12-30
US20230365642A1 (en) 2023-11-16
EP4172216A4 (en) 2024-12-04
JP2023532273A (ja) 2023-07-27
WO2021258213A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CN116390744A (zh) 双功能性超级因子及其用途
US12338269B2 (en) IL-2 superagonists in combination with anti-PD-1 antibodies
CN109415409B (zh) Flag标记的cd19-car-t细胞
US20220347268A1 (en) Il-4r as a biomarker in cancer
US12404497B2 (en) Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
CN113056284A (zh) 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法
KR20240026507A (ko) 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
EP2091972B1 (en) Multi-modal cancer therapy using viral hitch-hiking
WO2023248009A1 (en) Dosing methods for use with il-2 superagonists, agonists, and fusions thereof
CN119156405A (zh) Il-2、il-13和il-4细胞因子双功能性分子的用途和方法
EP4735483A2 (en) Il-2 fusion proteins
KR20260057409A (ko) Il-2 융합 단백질
WO2026030625A1 (en) Therapeutic compositions and methods for treating cancer
KR20260030127A (ko) Il-12 안정성 변이체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination